SMi's 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will bring together senior industry figures from big pharma, biotech and academia discussing recent updates and highlighting strategies to deal with the latest P&R developments through keynote addresses, case studies and roundtable discussions. International changes in policy will also be highlighted, along with an in-depth focus on biosimilar dugs and the impact that they have had on P&R through nations across Europe.Benefits of attending:• Evaluate new models for European reimbursement• Develop understanding of tiered pricing options with case studies from GSK• Gain further insight into current HTA policies• Receive invaluable information from field leaders through in-depth case studies• Learn about changes in UK P&R policy following the UK elections from industry bodies EMIG and the ABPISpeaker Panel includes: • Leslie Galloway, Chairman, Ethical Medicines Industry Group• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs• Janice Haigh, Practice Leader Market Access, Quintiles• Ken Walsh, Head Emerging Markets Pricing, GSK• Toros Sahin, Head of Market Access & Health Economics, Sanofi Turkey• David Watson, Director of Pricing & Reimbursement, ABPI• Alexander Roediger, Director European Union Affairs, MSD• Leyla Hannbeck, Head of Pharmacy, National Pharmaceutical Association Ltd• Eric Low, CEO, Myeloma UKThe conference will also feature an interactive post-conference workshop on: HTA Uncovered, led by Anke Van Engen, Chief Development Officer and Janice Haigh, Practice Leader Market Access, Quintiles, taking place on the 7th October 2015 in London.